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AIM OF THE STUDY 
To identify the factors associated with quality of life in patients on maintenance 
hemodialysis. 
Introduction 
Chronic kidney disease (CKD) and end stage renal disease (ESRD) have 
become worldwide public health problems. Both of these conditions increase 
the patient morbidity and mortality risks and produces major economic strain on 
the health-care systems. The average incidence of chronic kidney disease stage 5 
(CKD5) in developing countries is 150 per million population and in India it has 
been estimated to be 175 – 225 per million population.1 The incidence rates of 
ESRD have been on the increase from 49.9 patients per million  population in 
2000 to 63.8 patients per million of population in 2006, an almost 28% increase 
over a 6 year period.2 In India,  the incidence of CKD5 is increasing, but due to 
socioeconomic limitations only 10% of these patients receive renal replacement 
therapy .3   
As per the 5 year cumulative annual report of CKD registry of India presented 
in 41st Annual Conference of Indian Society of Nephrology, around 50% of 
patients reported to have CKD were in stage5 CKD (CKD5) and 62% of these 
reported patients in CKD5 were treated in conservative line, 39% receive 
maintenance hemodialysis (MHD), 4.5% receive continuous ambulatory 
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peritoneal dialysis (CAPD) and 2% receive kidney transplantation as their renal 
replacement therapy. So MHD remains the preferred modality of renal 
replacement therapy by most of the patients. 
 Various advances have taken place in the field of hemodialysis over the past 
two decades, but the quality of life in hemodialysis patients is poor and needs 
improvement. Previous studies have shown that hemodialysis is associated with 
complications like depression, cognitive impairment in the form of memory loss 
leading on to a poor quality of life.2 The complications of CKD like anemia, 
malnutrition, increased susceptibility to infection and increased rate of 
cardiovascular events further decreases the quality of life in these patients. To 
achieve an improvement in quality of life (QOL), it is required to identify 
factors that contribute for poor  QOL.17,47,48 Of these factors, many are 
potentially modifiable, if modified might reflect with improvement in QOL. 
This study was conducted to assess the determinants of quality of life in 
maintenance hemodialysis (MHD) patients. 
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REVIEW OF LITERATURE 
Hemodialysis is a process of removal of the toxins accumulated in the patient’s 
body as a result of either complete or incomplete loss of functioning kidney. 
This is performed by two processes diffusion and convection. The former one is 
the predominant way of solute clearance in intermittent hemodialysis performed 
2 – 3 times per week. The patient survival remains considerably low in patients 
on maintenance hemodialysis when compared to the renal transplant recipients. 
Various factors related to the patient and the procedure determines the quality of 
life and patient survival. So measures to improve the quality of life and patient 
survival have to be sought for on a continuous basis in all hemodialysis units. 
Bodies like Kidney Disease Outcomes Quality Initiative (KDOQI)4 and Kidney 
Disease: Improving Global Outcomes (KDIGO)5 had published clinical practice 
guidelines with a set of targets to be achieved in various aspects of hemodialysis 
like dialysis adequacy, anemia control, and mineral bone disease in 
management of CKD patients. 
The Review of literature pertaining to our topic revealed various types of 
assessments of the quality of life with usage of various clinical targets as 
outcome determinants. Many of the patients on MHD suffer from impaired 
cognitive functioning, unhealthy physical, mental, and social aspects of life that 
affect the simplest activities of daily life6 and the patients with poorer QOL 
score have increased mortality risks.7 Similar studies in the past have shown that 
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an improvement in QOL reduces the complications associated with this disease, 
or at least makes them more tolerable.2 
Due to financial constraints faced by the people in India , many patients ask for 
twice weekly dialysis schedule, reuse of dialyzers and have problems in 
compliance with the prescribed medicines especially erythropoietin.8 So 
anemia, malnutrition are the main reasons for impaired QOL in the subset of 
population. This study is conducted to assess the impact of various 
demographic, clinical and biochemical variables on the QOL of the patients. 
 
Anemia in hemodialysis 
Prevalence of anemia is high in patients on maintenance hemodialysis. Many 
symptomatology in ESRD patients like depression, fatigue, decreased exercise 
tolerance and cardiovascular consequences, such as left ventricular hypertrophy 
(LVH) and left ventricular systolic dysfunction were explained by anemia. 9 An 
association with an increased risk of morbidity and mortality principally due to 
cardiac disease and stroke was also shown.10-13 The prevalence of absolute and 
functional iron deficiency is high in patients with CKD and increases once the 
patient is started on erythropoiesis stimulating agents (ESA). This is due to the 
increment in iron requirement that happens after initiation of ESA. The National 
Kidney Foundation (NKF) Dialysis Outcomes Quality Initiative (KDOQI) 
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guidelines for the anemia 2007 update for the hemoglobin (Hb) target 
recommends that the selected Hb target should generally be in the range of 11 to 
12 g/dL in all patients with CKD 14. They also recommend that the Hb target 
should not exceed 13 g/dL.  
The main reason for high prevalence of anemia in spite of the usage of ESAs is 
iron deficiency. The dialysis patient has an estimated iron loss of 2gm per year 
principally through bleeding, blood drawing, and/or, most important with 
hemodialysis, the dialysis treatment itself. There are two types of iron 
deficiency that happens in patients on MHD – Absolute and Functional Iron 
deficiency.  
Absolute iron deficiency is a condition of low iron stores in the body as 
reflected by low serum ferritin level of less than 200 ng/ml in hemodialysis 
patients with low transferrin saturation (TSAT)  of  less than 20% calculated by 
formula as follows.15 
TSAT = Plasma Iron / Total iron binding capacity (TIBC) X 100 
Functional iron deficiency is characterized by the presence of adequate iron 
stores, but an inability to sufficiently mobilize this iron to support increasing 
erythropoiesis that happens with the administration of erythropoietin (EPO). 
The serum ferritin level is either normal or markedly elevated (greater than 200 
ng/ml) but the transferrin saturation (TSAT) typically below 20 percent.16 
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In a similar study conducted in the past, patients with higher hemoglobin levels 
had statistically significant positive correlation with higher QOL scores 3, 17 and 18. 
Erythropoietin usage in patients with anemia has been showed to improve the 
QOL score and exercise tolerance in MHD patients.19 We sought to see if any 
difference in QOL scores in patients with and without anemia, and subgroup 
analysis with those with absolute iron deficiency and functional iron deficiency, 
those on erythropoietin and not on erythropoietin. 
Nutrition in Hemodialysis 
Malnutrition is estimated to occur in 20 to 70 percent of patients and depends on 
the method of assessing nutritional status) and longer dialysis vintage (length of 
time in months or years spent on dialysis) is associated with faster decline in 
nutritional parameters of the patient.20,21 The most common and easily treatable 
cause for malnutrition in patients on maintenance dialysis is under dialysis – 
leading on to decreased taste acuity and anorexia secondary to uremia. 
The other causes of malnutrition in adequately dialyzed patients are: 
1. Nutrients losses into the dialysate. The average protein loss can vary from    
4 to 8 gm/day with renal replacement therapy like hemodialysis. Certain 
reuse procedures result in increased losses of protein into dialysate. Protein 
loss may go up to 20 grams in one hemodialysis session has been reported 
with polysulfone dialyzers reused with bleach. 22,23 
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2. Occult systemic illness producing an inflammatory response which 
increases the energy expenditure, pro-inflammatory cytokine levels, and 
oxidative stress provide a link between inflammation and malnutrition.24-26 
3. Dietary restrictions particularly salt restriction can make food less 
palatable. Furthermore, the encouragement to restrict fluid intake to 
minimize interdialytic weight gain may lead to a concurrent decrease in 
caloric intake.27 
4. Usage of bio-incompatible membranes may increase the protein losses. 
5. Persistent metabolic acidosis increases the protein degradation and amino 
acid oxidation.28 
6. Some medications, such as phosphate binders, can impair nutrient 
absorption.  
The presence of malnutrition is not only relevant to the nutritional status of the 
patient but also closely intertwined with the inflammation and cardiovascular 
morbidity and mortality.29 
There are various indicators of nutritional status in hemodialysis patients like 
serum albumin level, serum transferrin level, serum prealbumin level and 
normalized protein nitrogen appearance (nPNA).30 Of these markers, serum 
albumin and nPNA were used in our study to predict malnutrition. 
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1. Serum albumin level 
        It is accepted to be one of the important markers of malnutrition in CKD 
patients especially on MHD. Lower albumin level has been shown to be a 
predictor of low QOL3, 17, 18 As per the NKF-KDOQI guidelines for nutrition 
published in 2000; the target level of serum albumin in a predialysis sample was 
4 gm/dl for the brom-cresol method of estimation. The problem with usage of 
albumin as a marker of malnutrition is its lack of specificity in chronic 
inflammation. 58 
2. Protein nitrogen appearance (nPNA) 
It is widely misunderstood that the patients with low predialysis blood urea 
levels (Pre-BUN) are due to a good solute clearance happening with good 
hemodialysis. Patients with low predialysis blood urea nitrogen (Pre-BUN) 
might be secondary to two reasons. First is due to an adequate dose of dialysis 
producing a good urea clearance and second reason is due to the fact that patient 
is inadequately dialyzed and protein intake of the patient is low secondary to 
anorexia and altered taste which is caused by uremia. This is a situation where 
in one condition needs to be differentiated from the other condition for 
implementing corrective measures. This differentiation can be done by 
calculating the normalized protein equivalence of nitrogen appearance (nPNA), 
as an index of protein intake. This is also known as the normalized protein 
catabolic rate (nPCR). 
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Protein nitrogen appearance is a measure of the interdialytic appearance of urea 
in body fluids in addition to any urea lost in the urine in patients with residual 
renal function. It is an estimate of protein intake by the patient which can be 
calculated by using the following formulas. The correlation is good if the 
patient is not catabolic or anabolic. nPNA values of more than 1.2 and albumin 
level more than 3.5mg/dl has been shown to predict hospitalization and 
mortality in patients on MHD.31  
The National Cooperative Dialysis Study (NCDS) established that the timed 
average urea concentration and the protein catabolic rate (nPCR) were 
important determinants of morbidity and mortality in hemodialysis patients. 32 
The PNA in patients treated with hemodialysis is calculated as follows 33 
                                                                    (0.036 x ID rise in BUN x 24) 
  nPNA, in g/kg per day   =   0.22   +     ——————————————— 
                                                                                ID interval (hrs) 
 
Where the interdialytic (ID) rise in BUN is the difference between the pre-BUN 
of the present session and the post-BUN of the previous dialysis session and the 
ID interval is calculated in hours as the time in between the previous session 
and the present session. A total of three readings of PCR were calculated and 
the mean was taken. 
The patients with significant residual renal function (assumed by having a urine 
output of greater than 100ml/day) were expected to have a significant amount of 
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nitrogen losses in the urine and the same was accounted for by adding the value 
derived out of the following formula 
 The value derived out of the following formula was added to the nPCR value.  
                                                                           Urinary urea nitrogen (g) x 150 
  Total Urinary nitrogen loss in ID period =   —————————————— 
                                                                            ID interval (hrs) x weight (kg) 
 
 
Where the urinary urea nitrogen is the amount of the urea nitrogen excreted in a 
urine collection obtained during the interdialytic interval. 
As per the European and American hemodialysis guidelines, the target nPNA is 
1.0 to 1.2g/kg/day or higher.34, 35 
Similar studies in the past have shown positive correlation of higher albumin 
levels with higher QOL scores.3,17 
3. Serum Creatinine level 
The Predialysis serum creatinine gives an estimate of the sum of dietary intake 
of creatine and creatinine rich foods and the endogenous production from 
muscle breakdown minus the extracorporeal removal, urinary excretion 
secondary to the tubular secretion. So individuals with low predialysis serum 
creatinine less than 10mg/dl should be suspected for malnutrition and further 
worked up to rule out the same. Excess mortality risk was shown to be 
associated with low predialysis creatinine level lesser than 9 to 11 mg/dl.59 
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Dialysis adequacy 
KDOQI guidelines for hemodialysis adequacy recommend at least monthly 
assessments of delivered doses for timely diagnosis of under dialysis and 
pursuance of corrective measures.4 The most comprehensive way of measuring 
dialysis adequacy is urea kinetic modeling. Urea kinetic modeling is method 
used for verification of the equivalence between the prescribed dialysis (the 
prescribed Kt/V) and dialysis delivered (the effective Kt/V). It  also gives an 
estimate of  urea generation,  a marker of the protein catabolic rate and  protein 
intake 
 Kt/V is defined as the clearance of urea by the dialyzer (K, provided by 
manufacturer in mL/min which needs periodic verification by the dialysis 
personnel) multiplied by the duration of the dialysis treatment (t, in minutes) 
divided by urea’s distribution volume in the body (V, in mL), which is 
approximately equal to the total body water. 
 This correction of total urea removal (Kt) to the volume of distribution is 
essential because, the weight and the body surface area difference might change 
with individual to individual. So for example 150 ml of urea clearance might be 
adequate for a small framed patient but inadequate solute removal in a large 
patient. Two types of kt/v measurements are available (single pool kt/v and 
equilibrated kt/v). The difference between the two types is as follows. Single-
pool kt/v considers the distribution volume of urea as single but the equilibrated 
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kt/v considers the distribution volume of urea as two compartments and 
includes the correction of the equilibration that happens between the two 
compartments. 
As stated in the 2006 K/DOQI guidelines, the preferred method for 
measurement of the dialysis dose is by formal kinetic urea modeling .4 There is 
no universally accepted target value for the Kt/V. The 2006 K/DOQI clinical 
practice guidelines suggest that the minimally adequate dose of dialysis is 
achieving spKt/V of 1.2 per dialysis in patients on thrice weekly dialysis 
without residual renal function (eGFR<2ml/mt) and the target dose is spKt/V of 
1.4 per dialysis session without significant residual renal function also 
recommend that the minimum session spKt/V can be reduced in patients with 
minimal residual renal function (greater than 2 mL/min per 1.73 m2). This 
recommendation was based on the conclusion of the landmark trial in the area 
called HEMO study which was performed in 1846 patients. 
Studies in the past have showed higher QOL scores in patients achieving the 
target adequacy measures (Kt/V) 36, 37. So we measured spKt/V in our patients in 
three consecutive sessions and taken a mean of the values and correlated with 
the QOL scores. 
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Mineral bone disorder in CKD 
Chronic kidney disease is associated with various abnormalities in homeostasis 
of calcium (Ca), phosphorus (Pi), vitamin D and parathormone (PTH) with 
subsequent deleterious effects on bones and vasculature. 
The pathophysiology of bone disease is secondary to  
(1)  Decline in GFR with decreased phosphorus excretion leading to 
hyperphosphatemia  
(2)  Decreased synthesis of calcitriol (dihydroxyvitamin D3) or in the failing 
kidneys 
(3)  Secondary hyperparathyroidism with high parathormone levels  
(4)  Hypocalcemia secondary to decreased absorption in gastrointestinal tract 
due to decreased calcitriol levels.  
The bone disease varies from high turnover bone disease to low turnover bone 
disease. High turnover bone disease or osteitis fibrosa cystica is caused by high 
PTH levels with loss of tensile strength of bone making it more susceptible for 
fractures. On the other end of the spectrum is the adynamic bone disease 
characterized by reduced bone volume and mineralization caused due to 
oversupression of PTH levels with calcitriol. In addition to the changes in bone 
metabolism, abnormal calcium phosphorus homeostasis also leads to 
extraosseous calcification in soft tissues and vessels.  
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High phosphorus levels have been shown to be a predictor of morbidity and 
mortality in maintenance hemodialysis patients.38,39  
In a large US based study conducted in hemodialysis patients, an association 
between high calcium phosphorus product (Ca-Pi) and risk of death was 
showed. 38 The available evidence is convincing that the outcomes like 
increased death rate and extra skeletal calcification are related to Ca-Pi product 
once the product exceeds 55. The goal level of Ca-Pi product should be below 
55. In a similar study conducted by veerappan et al, there was a tendency of 
lower QOL scores with increased calcium and phosphorus levels.3 
Hyperphosphatemia, hypercalcemia, elevated Ca-Pi product, calcitriol 
deficiency and increased PTH levels are probable contributors for high 
incidence of cardiovascular mortality 
As per KDOQI clinical practice guidelines for Bone Metabolism and Disease in 
Chronic Kidney Disease published in 2003, the target serum Pi is less than 
5.5mg/dl, the serum Ca should be maintained within  the normal range (8.4 to 
9.5 mg/dl) and the Ca-Pi product of less than 55.40 
So we sought to see the correlation of QOL scores with the different levels of 
serum calcium (Ca), serum phosphorus (Pi) and calcium-phosphorus product 
(Ca-Pi) product. 
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Demographic variables 
The variables like age, sex, duration of dialysis, economic status, educational 
status, marital and employment status are known to have an effect on the QOL 
experienced by the patient.  In the previous studies, older patients and female 
sex are the groups shown to have lower QOL scores.3, 17, 18, and 41  
Patients, who are educated, employed and those with better economical status 
have been shown to have better QOL score.17, 18       
Dialysis vintage is referred to the length of time on dialysis in months or years. 
Usually it is expected to be a negative predictor of QOL since the propensity of 
patients to develop complications like vascular access failure is high in long 
term. But studies conducted in the past had showed mixed results. Some studies 
showed association of longer dialysis vintage with higher QOL scores in some 
studies 3 and with lower QOL scores in some studies.41   
Travel time to the dialysis centre has been shown to have a negative impact on 
QOL scores in the previous studies.3, 42 Marital status has been shown to have a 
positive impact on QOL scores in some studies.17  
Clinical variables like type of the native kidney disease and the number of co 
morbidities are known to affect the QOL scores, since they affect the health of 
the patient in a negative manner. Previous studies have shown that patients with 
native kidney disease of diabetic nephropathy have poor QOL scores compared 
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to other causes for ESRD.41The number of co morbidities has an inverse 
correlation with the QOL scores was showed in some studies .17 
Serological status and vascular access  
Chronic Hepatitis C virus (HCV) infection is one of the potential problems 
arising globally in hemodialysis units with a mean prevalence of 13.5% and 
varies across countries ranging from 2.6% to22.9%.43 Not only adding on to the 
co morbidities, a recent meta-analysis shows that anti-HCV positive status is an 
independent and significant risk factor for death. Evidence from previous 
studies shows that QOL scores especially in the mental aspects is substantially 
impaired in anti-HCV positive patients.44 
Chronic Hepatitis B virus (HBV) infection is also a potential problem with a 
recent study showing a prevalence of 16.8 percentages in hemodialysis patients 
45
. But the QOL studies in hemodialysis patients with hepatitis B infection were 
searched and not able to be traced. Studies in patient population with HBV 
infection (not on hemodialysis) showed that QOL scores were less in the 
patients with advanced disease.46 
Vascular access for hemodialysis is the lifeline for patients on maintenance 
hemodialysis. Access related complications remain one of the most important 
causes for hospitalizations and morbidity. Previous studies have shown that 
patients with current access with double lumen catheter use for hemodialysis 
had lower QOL scores.3, 17, and 37 
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MATERIALS AND METHODS 
This was a cross-sectional study conducted in a tertiary maintenance 
hemodialysis unit in patients who were on maintenance hemodialysis for a 
period more than 3 months. The dialysis prescription was empiric and the 
frequency of the dialysis sessions was decided by the clinical status of the 
patient. The patients with recent acute ailments like severe sepsis, trauma or 
fractures were excluded from the study. The inclusion criteria were: ESRD 
patient who were aged 18 years or more; on regular twice or thrice weekly 
hemodialysis and able to provide informed consent. An informed consent was 
obtained from the participating patients. Ethical approval was obtained from the 
In-hospital/Institutional ethical committee. Clinical information was collected 
by a study co-coordinator and entered in a proforma that is attached. 
Assessments 
1. Demographic information ( age, sex, educational status, financial and marital 
status), information regarding the duration of time to reach the dialysis centre, 
dialysis vintage, co-morbidity index, native kidney disease were collected by 
interview with the patients and review of the medical records of the patient.  
2.  Blood samples were drawn predialysis and post dialysis according to the 
recommendation by KDOQI following slow-flow methods (reducing the blood 
flow rate to 100ml/mt and sampling after waiting for 15 seconds). spKt/V was 
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calculated from using predialysis and post dialysis urea levels, post dialysis 
weight of the patient, ultra filtration volume and calculated using the daugirdas 
formula fed into a computer.49 The same procedure is repeated in three 
consecutive hemodialysis sessions and the mean value was taken into account.  
3. Protein nitrogen appearance (nPNA) was calculated using the Gotch 
formula.50 The patients with residual urine output greater than 100ml/day were 
selected and asked to collect the urine passed during the interdialytic period.  
Urine urea levels were calculated and the PNA value was corrected for patients 
with residual kidney function using the formula mentioned in review of 
literature.51   
4. Biochemical studies performed were markers of nutrition like serum albumin 
measurement, anemia profile including the serum hemoglobin (Sr.Hb), serum 
ferritin, serum transferring saturation (Sr.TSAT) was calculated from the 
measurements of serum iron and total iron binding capacity. 
5. Information regarding erythropoietin use, serological status, catheter use were 
obtained from the records in the dialysis unit, absolute iron deficiency (AID) 
was defined as serum ferritin < 200, Sr.TSAT < 20, functional iron deficiency 
(FID) was defined as serum ferritin >200, Sr.TSAT < 20.  
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6. We arbitrarily divided the total sample size into groups’ bases on their 
demographic and clinical characteristics and the QOL scores were compared in 
between the groups. 
Bio- Chemical analysis 
All biochemical analysis was performed with fully automated Cobas Integra 
analyzer Model 400. Blood urea and urine urea level was measured using the 
principle of Kinetic test with urease and glutamate dehydrogenase method. 
Creatinine estimation was done by buffered kinetic jaffe reaction without 
depolarization. Serum iron was measured by guanidine/Ferro Zine method. 
Serum ferritin was estimated using electrochemiluminescence immunoassay. 
Unsaturated iron binding capacity was estimated using direct determination 
using Ferro Zine method. Total protein was estimated using the principle of 
Biuret reaction (divalent copper reacts with peptide bonds of protein to produce 
a change in color which was read with colorimeter. Serum albumin estimation 
was done using modified brom cresol green binding assay. Calcium level was 
measured by schwartzenbach with o-cresolphthalein complexone method. 
Inorganic phosphate was measured was estimated with endpoint method with 
sample blanking method. Hemoglobin estimation was performed by Beckman 
Coulter analyzer LH 750. Anti-HCV, anti-HIV, hepatitis B surface antigen 
(HbsAg) was performed by chemiluminescence method. 
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Instrument for assessing QOL 
Quality of life was assessed by world health organization QOL questionnaire 
(WHOQOL-BREF). The same was used in a validated Tamil version..52 The 
instrument was used after obtaining the permission from WHO. The 
questionnaire was filled up by the patients within a period of one month from 
the clinical data entry. 
Four domains are defined for the WHOQOL-BREF, based on its 24 items:  
1. Domain 1- physical health domain, includes questions on activities of 
daily living, dependence on medicinal substances and medical aids, 
energy and fatigue, mobility, pain and discomfort, sleep and rest, and 
work capacity. 
2. Domain 2 - psychological health domain, includes questions on bodily 
image and appearance, negative feelings, positive feelings, self-esteem, 
spirituality, religion, personal beliefs, thinking, learning, memory, and 
concentration.  
3. Domain 3, social health domain includes questions on social 
relationships, covers personal relationships, social support, and sexual 
activity.  
4. Domain 4, environment health domain, includes questions on financial 
resources, freedom, physical safety and security, home environment, 
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physical environment (pollution, noise, traffic, and climate), and 
transport. 
Scoring of WHOQOL-BREF 
The questionnaire was scored after its administration to the study subjects and 
then the raw score of each domain was then transferred to standardized score of 
4 to 20, in order to maintain uniformity in the scores. The method of inferring 
the score is available elsewhere.52 Higher scores means better quality of life of 
patients. The QOL scores of each domain and the Total QOL score were 
compared between the groups of the patients.  
Validation of WHOQOL-BREF questionnaire 
The World Health Organization Quality of Life (WHOQOL – 100 with 100 
items and shorter version WHOQOL –BREF with 26 items are cross-culturally 
validated generic instruments available in 30 languages, including Hindi and 
Tamil, and the scale was developed across 15 centers internationally.52 The 
WHOQOL scales are the second most commonly used health related quality of 
life (HRQoL) instrument in the world.53 
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Statistical Methods: 
1. Descriptive statistics were reported as number and percentages for 
categorical variables, mean and SD for continuous variables. 
2. Normality of the data was checked. 
3. Independent t test or ANOVA for the parametric and Wilcoxon rank sum 
test or Kruskal Wallis test for non-parametric was used to compare the 
QOL between the groups.  
4. Pearson or Spearman’s Rank Correlation was used to assess the 
relationship between quality of life and clinical characteristics, as 
appropriate.  
5. Statistical analysis was done using SPSS software version 18. 
6.  Probability value less than 5% was considered as statistically significant. 
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RESULTS 
Study design: An observational clinical study with 105 patients is undertaken 
to study the Quality of life of hemodialysis patients 
 
Table 1: Age distribution of patients studied 
 
Age in years Number of patients % 
21-30 12 11.4 
31-40 19 18.1 
41-50 25 23.8 
51-60 28 26.7 
61-70 16 15.2 
71-80 5 4.8 
Total 105 100.0 
Mean ± SD: 48.28±13.00 
 
 
Figure - 1 
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Table 2: Gender distribution of patients studied 
 
 
Gender Number of patients % 
Male 71 67.6 
Female 34 32.4 
Total 105 100.0 
 
 
 
Figure - 2 
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Table 3: Education distribution of patients studied 
 
 
Education Number of patients % 
Nil 7 6.7 
1-9 42 40.0 
10th/PUC/Diploma 43 40.9 
Graduate 9 8.6 
Post graduate 4 3.8 
Total 105 100.0 
 
 
Figure - 3 
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Table 4: Marital status 
 
 
 
Marital status Number of patients % 
Not married 12 11.4 
Married 93 88.6 
Total 105 100.0 
 
 
 
Figure - 4 
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Table 5: Employment status 
 
 
 
Employment 
status 
Number of 
patients % 
Not employed 82 78.1 
Employed 23 21.9 
Total 105 100.0 
 
 
 
 
Figure – 5 
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Table 6: Income in Rupees 
 
 
 
Income in Rs Number of patients % 
<10000 9 8.6 
10000-50000 29 27.6 
50000-100000 41 39.1 
100000-200000 18 17.1 
>200000 8 7.6 
Total 105 100.0 
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Baseline Characteristics 
 
 
Table 7: Duration of dialysis in months 
 
 
 
Duration in 
months 
Number of 
patients % 
1-10 29 27.6 
11-20 22 20.9 
21-30 16 15.2 
31-60 26 24.8 
>60 12 11.4 
Total 105 100.0 
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Baseline Characteristics 
 
 
Table 8: Travel time 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure - 8 
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Travel time
< 30 min
30 - 60 min
> 60 min
Travel Time Number of patients % 
 < 30 min 13 12.3 
 30 – 60 min 43 40.9 
>60 min 49 46.6 
Total 105 100.0 
31 
 
Baseline Characteristics 
 
 
Table 9: Frequency of dialysis per week 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure - 9 
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Number of dialysis/week
2 / week
3 / week
Dialysis 
frequency 
Number of 
patients % 
      2 / week  61 
 
58.10 
      3 or more / 
wk 
 
44 
 
41.90 
Total 105 100.0 
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Baseline Characteristics 
 
 
Table 10: Native kidney disease 
 
 
NKD Number of patients % 
DN 36 34.3 
GN 11 10.5 
ADPKD 2 1.8 
OTHERS 1 0.9 
NOT KNOWN 55 52.4 
TOTAL 105 100.00 
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Baseline Characteristics 
 
 
Table 11: Co morbidities 
 
 
Co Morbidities 
Number of 
patients 
(N=105) 
% 
SHT 61 58.1 
SHT/DM 31 29.5 
SHT/IHD 6 5.7 
DM/SHT/IHD 5 4.8 
TOTAL 105 100.00 
 
 
 Figure - 11 
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Baseline Characteristics 
 
1. Baseline characteristics of 105 patients who responded to the WHO-QOL 
BREF questions no more than 30 days from completion of the 
questionnaire are shown in Tables-1 – 11 & Fig. 1-11 
2. Among 105 patients on hemodialysis, there was a mixture of all ages seen 
in the study population. 
3. Among the study population, 71(67%) were men 93(88%) were married. 
4. Most of the patients in study population were unemployed 82(78.1%) and 
most of them 61(58%) were on twice weekly dialysis. 
5. Most of the patients had their travel time to centre greater than 30 
minutes ( Table & Figure – 8) 
6. Most of the patient’s native kidney disease were undiagnosed (52.4%) 
followed by diabetic nephropathy (34.3%) ( Table & Figure – 10) 
7. More than 90% of the study population has hypertension as comorbidity 
and around 30% of the population has diabetes. (Table & Figure – 11) 
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Table 12: Clinical characteristics of the study subjects 
 
 
Variables Number Percentage 
 
Hb                                   
                                  <10 
                              >10 
 
93 
12 
 
88.57 
11.43 
Kt/v                              
                                 >1.2 
                             <1.2 
 
49 
56 
 
46.67 
53.33 
nPCR                               
                                   <1 
                            >1 
 
18 
87 
 
17.14 
82.86 
Albumin                        
                                    <3.5 
                                   >3.5 
 
7 
98 
 
6.67 
93.33 
Serology        
                                      B 
                                      C 
                                      N    
                                                 
 
 
6 
15 
84 
 
5.71 
14.29 
80.00 
Access                               
                                       C 
                                       F 
 
11 
94 
 
10.48 
89.52 
Serum ferritin                 
                                  <200 
200 – 499 
500 – 800 
>800 
 
 
 
36 
35 
16 
17 
 
  
 
34.62 
33.65 
15.38 
16.35 
TSAT 
                                  <20 
                               20 – 40 
                                 >40 
 
29 
43 
5 
 
37.66 
55.84 
6.49 
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Clinical characteristics of the study subjects 
 
 Figure – 12 – Anemia status 
 
 
 
 
 
      
 
 
1. Around 88 % of the study population had anemia. 
2. 35 % had iron deficiency reflected by low ferritin or transferrin 
saturation levels. 
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Clinical characteristics of the study subjects 
 
 
Figure – 13 – Dialysis adequacy 
 
 
  
 
 
 
 
Around 50 % of the study population had adequate dialysis reflected by spKt/V 
of 1.2 
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Clinical characteristics of the study subjects 
 
 
Figure – 14  
 
 
 
 
 
 
There was a high prevalence rate native arteriovenous fistula as the vascular 
access in around 90 % of the study population. 
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Clinical characteristics of the study subjects 
Nutritional status 
 
Figure – 15  
 
 
 
 
Figure – 16  
 
 
 
 
1. Around 93% of the study population had albumin level greater than 
3.5mg/dl  
2. 80% of the population had PNA value greater than 1. 
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Clinical characteristics of the study subjects 
Figure – 17 
 
 
 
 
Figure – 18 
 
 
 
 
1. Around 40% of the population had their calcium phosphorus product 
greater than 50. 
2. 80 of the study population were seronegative, 14 % were seropositive for 
hepatitis C and 5 % were seropositive for hepatitis B  
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Clinical characteristics of the study subjects 
 
 
Table – 13 – Mean values of the study variables expressed as mean ± 
standard deviation 
 
Variables Mean ± S.D 
Hb in gm% 8.00 ± 1.72 
Kt/v  1.22 ± 0.36 
nPCR  1.51 ± 0.60 
Albumin in mg/dl 4.06 ± 0.41 
Ca-Pi product 46.15 ± 14.93 
TSAT 24.00 ± 11.18 
Calcium in mg/dl 8.54 ± 1.01 
Phosphorous in mg/dl 5.44 ± 1.77 
Creatinine in mg/dl 9.56 ± 2.84 
Erythropoietin  dose in IU per week  6052.63 ± 2438.00 
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Table 14: Comparison of Quality of life between demographic 
characteristics 
 
Variable 
Quality of Life 
Domain1 Domain2 Domain3 Domain4 Total QOL 
Gender 
Male  
Female 
 
11.6 ± 2.1 
11.5 ± 1.6 
 
11.4 ± 2.2 
11.3 ± 2.0 
 
12.1 ±3.6 
12.7 ± 2.9 
 
12.4 ± 2.4 
13.2 ± 2.0 
 
47.5 ± 8.2 
48.6 ± 6.1 
Marital  
Married 
Not-married 
 
11.6 ± 2.0 
11.2 ± 1.5 
 
11.4 ± 2.2 
11.0 ± 1.5 
 
12.5 ± 3.4 
10.4 ± 2.8* 
 
12.6 ± 2.3  
12.5 ± 2.3 
 
48.2 ± 7.8 
45.1 ± 5.5 
Employment  
Employee 
Not-employed 
 
12.1 ± 1.4 
11.5 ± 2.1 
 
12.2 ± 1.7 
11.2 ± 2.2* 
 
13.0 ± 2.9 
12.1 ± 3.5 
 
12.7 ± 1.8 
12.6 ± 2.4 
 
49.9 ± 5.1 
47.3 ± 8.1 
Education 
Illiterate 
Up to middle 
High school 
Graduates level 
 
11.4 ± 1.3 
11.7 ± 1.9 
11.6 ± 2.2 
11.2 ± 1.7 
 
11.8 ± 2.1 
11.2 ± 1.9 
11.5 ± 2.1 
11.1 ± 2.7 
 
14.3 ± 2.6 
12.1 ± 3.3 
12.2 ± 3.4 
11.9 ± 2.8 
 
12.3 ± 0.9 
12.7 ± 2.1 
12.6 ± 2.3 
12.6 ± 3.0* 
 
49.8 ± 3.4 
47.8 ± 7.1 
47.9 ± 7.8 
46.9 ± 9.2 
No per week 
2 
3 
 
11.6 ± 1.6 
11.5 ± 2.3 
 
11.1 ± 1.6 
11.7 ± 2.7 
 
12.5 ± 3.4 
12.0 ± 3.3 
 
12.6 ± 2.1 
12.7 ± 2.6 
 
47.9 ± 6.5 
47.8 ± 8.9 
Dialysis vintage 
 
< 6 months 
6-12 months 
13-24 months 
>24 
 
 
12.3 ± 1.7 
11.6 ± 1.8 
11.9 ± 1.9 
11.2 ± 2.0 
 
 
12.1 ± 1.7 
11.3 ± 2.1 
11.9 ± 2.1 
10.9 ± 2.2 
 
 
13.9 ± 3.9 
13.3 ± 3.2 
12.3 ± 3.0 
11.4 ± 3.4 
 
 
13.9 ± 2.1 
12.3 ± 2.5 
12.6 ± 2.5 
12.5 ± 2.3 
 
 
52.2 ± 7.5 
48.3 ± 7.1 
48.8 ± 7.5 
46.0 ± 7.6 
Time in hours 
<30 min 
30-60 min 
>60 min 
 
11.7 ± 1.6 
11.6 ± 1.8 
11.5 ± 2.2 
 
11.7 ± 1.5 
11.5 ± 2.3 
11.2 ± 2.1 
 
13.1 ± 2.9 
11.9 ± 3.4 
12.4 ± 3.5 
 
12.7 ± 2.5 
12.8 ± 2.6 
12.5 ± 2.0 
 
49.1 ± 6.1 
47.7 ± 8.4 
47.6 ± 7.3 
Income 
<1 lakh 
1 to 3 lakh 
Above 3 lakh 
 
11.4 ± 2.1 
12.0 ± 1.6 
10.5 ± 2.1 
 
11.2 ± 2.3 
11.4 ± 1.6 
13.0 ± 0.1 
 
12.1 ± 3.5 
12.6 ±3.0 
14.5 ± 2.1 
 
12.4 ± 2.3 
12.9 ± 2.3 
15.0 ± 2.8 
 
47.1 ± 8.0 
48.9 ± 6.6 
53.0 ± 2.8 
* -p<0.05; Independent t test to compare between the groups 
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Comparison of Quality of life and demographic characteristics 
1. There was no gender difference in QOL scores and a low scores was 
noted in the social health domain in the unmarried population with a 
statistical significance. (p < 0.05). 
2. Being Un-employed was significantly associated with lower QOL scores 
in psychological domain (p < 0.05). 
3.  QOL scores in patients with an educational qualification of graduates 
level was associated with better QOL scores particularly in environmental 
health domain (p < 0.05). 
4. Interestingly, No difference was noted in between the groups on twice 
weekly and thrice weekly hemodialysis. 
5. Patients with higher income experienced a better QOL. Scores in the 
social relationship domain was lower in the unmarried patients (P < 0.05). 
6. Dialysis vintage & Time taken for travel to the dialysis unit had an 
inverse relation with the trend of QOL score but not statistically 
significant. 
7. The group with higher income (above 3 lakh rupees) had a higher QOL 
scores compared with the lower income groups but did not reach 
statistical significance. 
8.  There was no difference in QOL between the twice weekly and thrice 
weekly group. 
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Table – 15 - Comparison of Quality of life and clinical 
characteristics 
 
 
Variables 
Quality of life 
Domain 1 Domain 2 Domain 3 Domain 4 Total  
Albumin  
<3.5 
≥3.5 
 
9.9 ± 2.9 
11.7  ± 1.8 
 
9.4 ± 1.4 
11.5  ± 2.1* 
 
10.3 ± 1.6 
12.4  ± 3.4 
 
11.6  ± 2.7 
12.7  ± 2.3 
 
41.1  ± 6.1 
48.3  ± 7.5* 
PNA cat 
<1 
≥1 
 
11.1 ± 1.3 
11.7 ± 2.0 
 
10.9 ± 1.5 
11.4 ± 2.2 
 
12.9 ± 2.7 
12.2 ± 3.5 
 
12.7 ±2.1 
12.6 ±2.3 
 
47.6 ± 5.2 
47.9 ± 7.9 
Access  
C 
F 
 
11.7 ± 1.7 
11.6 ± 2.0 
 
11.6 ± 2.2 
11.4 ± 2.1 
 
13.1 ± 2.9 
12.2 ± 3.4 
 
12.5 ± 2.3 
12.6 ± 2.3 
 
48.8 ± 7.7 
47.7 ± 7.6 
spKt/V  
<1.2 
≥1.2 
 
11.6 ± 2.1 
11.6 ± 1.8 
 
11.2 ± 2.2 
11.6 ± 2.1 
 
12.0 ± 3.2 
12.5 ± 3.6 
 
12.4 ± 2.1 
12.8 ± 2.5 
 
47.2 ± 7.0 
48.5 ± 8.0 
Co-Morbidity 
Only 1 
More than 1 
Nil 
 
11.8 ± 2.1 
11.2 ± 1.6 
12.0 ± 1.4 
 
11.5 ± 2.2 
11.3 ± 2.1 
10.5 ± 0.7 
 
 
12.4 ± 3.3 
12.0 ± 3.5 
12.5 ± 4.9 
 
12.5 ± 2.2 
12.8 ± 2.5 
13.5 ± 2.1 
 
48.2 ± 7.6 
47.3 ± 7.6 
48.5 ± 9.2 
NKD 
DN 
GN + others 
NK 
 
11.2 ± 1.6 
11.4 ± 1.9 
11.9 ± 2.1 
 
11.3 ± 2.1 
10.6 ± 1.4 
11.6 ± 2.3 
 
11.8 ± 3.6 
13.1 ± 2.9 
12.4 ± 3.3 
 
12.7 ± 2.6 
12.4 ± 2.1 
12.6 ± 2.2 
 
47.0 ± 7.9 
47.4 ± 6.9 
48.5 ± 7.5 
Serology  
    Hepatitis B 
    Hepatitis C 
Seronegative 
 
10.8 ± 3.6 
12.2 ± 1.7 
11.5 ± 1.8 
 
10.5 ± 2.1 
11.5 ± 1.6 
11.4 ± 2.2 
 
11.0 ± 2.7 
11.6 ± 2.7 
12.5 ± 3.5 
 
10.8 ± 1.9 
12.7 ± 2.0 
12.7 ± 2.3 
 
43.2 ± 7.9 
48.1 ± 6.1 
48.1 ± 7.8 
 
 
* -p<0.05; Independent t test or ANOVA to compare between the groups 
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Table – 15 (contd.,)- Comparison of Quality of life and clinical 
characteristics 
 
    Variables 
Quality of life 
Domain 1 Domain 2 Domain 3 Domain 4 Total 
Hb 
≤ 10 
Above 10 
 
11.5 ± 1.9 
12.4 ± 1.9 
 
11.3 ± 2.0 
12.2 ± 2.7 
 
12.2 ± 3.4 
12.5 ± 3.4 
 
12.5 ± 2.3 
13.2 ± 2.4 
 
47.5 ± 7.4 
50.3 ± 8.9 
Ferritin 
< 200 
200 – 499 
500 – 800 
>800 
 
11.5 ± 2.3 
11.6 ± 1.7 
10.9 ± 2.2 
12.2 ± 1.3 
 
11.8 ± 2.3 
11.1 ± 1.7 
11.1 ± 3.0 
11.3 ± 1.7 
 
13.2 ± 3.1 
12.1 ± 3.6 
11.7 ± 3.8 
11.4 ± 2.8 
 
13.0 ± 2.7 
12.2 ± 2.0 
13.1 ± 2.3 
12.5 ± 2.0 
 
49.5 ± 8.2 
47.0 ± 7.1 
46.7 ± 8.8 
47.5 ± 6.0 
TSAT 
<20 
20 and above 
 
11.6 ± 1.6 
11.6 ± 2.0 
 
11.9 ± 2.0 
11.2 ± 2.4 
 
13.1 ± 3.1 
12.2 ± 3.8 
 
12.8 ± 2.4 
12.7 ± 2.3 
 
49.4 ± 7.2 
47.7 ± 8.1 
Calcium 
<8 
8 – 10 
> 10 
 
11.7 ± 2.7 
11.5 ± 1.7 
11.8 ± 1.8 
 
12.0 ± 2.7 
11.1 ± 2.0 
12.6 ± 0.5 
 
12.5 ± 3.8 
12.2 ± 3.3 
11.8 ± 2.9 
 
13.2 ± 2.4 
12.4 ± 2.3 
12.6 ± 0.5 
 
49.5 ± 9.6 
47.3 ± 7.2 
48.8 ± 1.3 
Phosphorous 
≤ 5.5 
> 5.5 
 
11.3 ± 1.9 
11.9 ± 2.0 
 
11.0 ± 2.0 
11.7 ± 2.2 
 
12.0 ± 3.2 
12.5 ± 3.6 
 
12.5 ± 2.2 
12.7 ± 2.4 
 
46.8 ± 7.0 
48.9 ± 8.1 
CaxP 
<50 
≥50 
 
11.4 ± 1.9 
11.8 ± 2.0 
 
11.1 ± 2.1 
11.7 ± 2.2 
 
 
12.1 ± 3.3 
12.5 ± 3.6 
 
 
12.6 ± 2.3 
12.7 ± 2.3 
 
 
47.3 ± 7.4 
48.7 ± 7.9 
 
* -p<0.05; Independent t test or ANOVA to compare between the groups 
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Comparison of Quality of life and clinical characteristics 
 
1. Patients with serum albumin level greater than 3.5mg/dl had a better QOL 
scores in the psychological health domain and total QOL score (p<0.05).  
2.  No difference was noted between the groups of patients with higher or lower 
kt/v, PNA. 
3. Patients with more co-morbidity had lower scores; patients with native 
kidney disease of diabetic nephropathy had lower QOL score but neither 
reached statistical significance. 
4. Seronegative & Hepatitis C patients had comparable QOL scores but patients 
with hepatitis B patients had lower QOL scores but not statistically significant. 
5. Patients with Hb greater than 10gm% had better QOL scores but not 
statistically significant. 
6. There was no difference in QOL scores in the groups with different ferritin 
levels and TSAT levels. 
7. There was no difference in QOL scores in the groups with different levels of 
calcium, phosphorus or calcium-phosphorus product. 
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SUBGROUP ANALYSIS OF ANEMIC PATIENTS 
Iron Status Evaluation 
 
 
Table - 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure - 19 
 
       
 
 
1. Overall prevalence of anemia was 88% (93/105). 
2. Of those with anemia, 56% of patients had functional iron deficiency and 
only 18% had absolute iron deficiency. 
17
53
35
Anemic patients ( Hb < 10)
Absolute iron deficiency
Functional iron deficiency
Others
Iron status 
Number of 
patients ( Hb 
<10) 
% 
 Absolute iron deficiency 17 18.2 
Functional iron 
deficiency 53 56 
Remaining 23 24 
Total 93 100.0 
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QUALITY OF LIFE IN ANEMIA SUB-GROUP 
 
Table - 17 
 
Variable 
Quality of life 
Domain 1 Domain 2 Domain 3 Domain 4 Total QOL 
Absolute Iron 
deficiency 
 
  
 
11.3 ± 1.7 
 
 
11.6 ± 2.1 
 
 
12.9 ± 3.1 
 
 
12.8 ± 3.0 
 
 
48.6 ± 7.8 
Functional Iron 
deficiency 
 
 
11.5 ± 1.9 
 
 
11.1 ± 2.2 
 
 
12.0 ± 3.8 
 
 
12.6 ± 2.1 
 
 
47.2 ± 7.8 
 
Remaining 11.4 ± 2.0 11.4 ± 2.0 12.5 ± 3.0 12.4 ± 2.5 47.8 ± 7.0 
 
Figure - 20 
 
 
 
There was no difference in QOL scores noted in any of the domain with 
different groups based on the iron status. 
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Erythropoietin usage in anemic group and subgroups 
 
Figure – 21 
 
 
 
 
 
Figure - 22 
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QUALITY OF LIFE IN GROUPS BASED ON EYTHROPOIETIN USAGE 
Table - 18 
 
Variable 
                                             Quality of life 
Domain 1 Domain 2 Domain 3 Domain 4 Total QOL 
Erythropoietin usage 
Not used 
used 
 
11.3 ± 1.9 
12.0 ± 1.8 
 
11.1 ± 2.0 
11.8 ± 2.0 
 
12.5 ± 3.4 
11.7 ± 3.4 
 
12.4 ± 2.4 
12.9 ± 1.9 
 
47.2 ± 7.7 
48.4 ± 6.6 
Erythropoietin  dose 
<5000 
5000 – 10000 
>10000 
 
10.9 ± 2.1 
11.5 ± 1.8 
13.0 ± 2.8 
 
10.6 ± 2.2 
11.4 ± 1.9 
11.5 ± 0.7 
 
12.1 ± 3.5 
12.6 ± 3.2 
16.0 ± 0.0 
 
12.4 ± 2.0 
12.2 ± 2.7 
16.0 ± 1.4 
 
46.0 ± 7.8 
47.7 ± 7.5 
56.5 ± 3.5 
 
* -p<0.05; Independent t test or ANOVA to compare between the groups 
 
QOL SCORES BASED ON ERYTHROPOIETIN DOSE RECIEVED 
Figure - 23 
 
 
1. There was no difference noted in between the used group and not used group 
in QOL scores. (Table - 18) 
 
2. There was an increasing trend in QOL scores noted in patients with higher 
doses of EPO (Figure - 23) 
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5000 - 10000U/wk
>10000/wk
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Table 19: 
Pearson Correlation test between the Quality of life and the variables: 
 
 
 *   - p <0.05; ** - p < 0.01; Pearson or Spearman’s Rank correlation as 
appropriate 
 
Variables 
Quality of life 
Domain 
1 
Domain 
2 
Domain 
3 
Domain 
4 
Total 
QOL 
Age 
 
-0.2229* 
 
-0.1424 
 
-0.1550 
 
0.0354 
 
-0.1550 
 
Duration in months 
 
-0.0479 -0.0876 
 
-0.1603 
 
-0.0133 
 
-0.1108 
 
No./week 
 
-0.0297 
 
0.1287 
 
-0.0720 
 
0.0149 
 
-0.0018 
 
Erythropoietin  dose 
(N/ dose/wk) 
 
0.2446* 
 
0.2090 
 
0.2055 
 
0.1157 
 
0.3195* 
 
Kt/v 
 
0.0352 
 
-0.0749 
 
-0.0845 
 
-0.0579 
 
-0.0658 
 
nPCR 
 
-0.0662 
 
0.0555 
 
-0.0219 
 
-0.0233 
 
-0.0205 
 
Hb 
 
0.0865 
 
0.1614 
 
0.0194 
 
0.0922 
 
0.1077 
 
Calcium mg 
 
-0.0729 
 
-0.1093 
 
-0.0272 
 
-0.0786 
 
-0.0878 
 
Phosphorus mg 
 
0.0755 
 
0.1774 
 
0.0581 
 
0.1182 
 
0.1328 
 
Ca XP 
 
0.0417 
 
0.1103 
 
0.0429 
 
0.0801 
 
0.0860 
 
Creatinine  
 
0.1719 
 
0.1261 
 
-0.0479 
 
0.0548 
 
0.0756 
 
Albumin 
 
0.2888** 
 
0.1768 
 
-0.0304 
 
-0.0138 
 
0.1074 
 
Calcium alb 
 
-0.1639 
 
-0.1641 
 
-0.0171 
 
-0.0730 
 
-0.1208 
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Pearsons or Spearman’s Rank correlation between the QOL and variables  
 
1. There was a significant negative correlation in physical health domain for 
age. ( p < 0.05) 
2. There was a significant positive correlation in physical health domain for 
albumin. ( p < 0.01) 
3. There was a significant positive correlation in physical health domain and 
Total QOL for Erythropoietin dose (N/ dose/wk). 
4. There was positive correlation noted in all domains with higher 
hemoglobin levels and higher phosphorus levels but the correlation did 
not reached statistical significance. 
5. There was a negative correlation noted with longer dialysis vintage and 
higher calcium levels but not statistically significant. 
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DISCUSSION 
 
Patients with End-stage renal disease (ESRD) on maintenance hemodialysis has 
lower quality of life in comparison to the general population.18, 47and 54 The scores 
observed in our study were comparable to the scores noted in a similar 
population.18  The problems with low QOL are its independent association with 
poor outcome7 and a risk of withdrawal of treatment.41 The various reasons for 
low QOL scores in patients on MHD are high incidence of depression, 41, 56 
secondary to their socio-economic factors, co-morbidities and complications 
secondary to ESRD, of which some factors are potentially modifiable and  
treatable.  
Correlation with demographic characteristics 
In the present study, the sample of patients was a mix of patients representing 
all age groups except pediatric age group. The baseline characteristics are 
comparable to other studies conducted in the same field in the past.3,18 
Of the demographic factors, higher age has a negative correlation with the QOL 
in all domains but has statistical significance only in the physical health domain 
(p< 0.05). The same finding was observed in other studies.3,18 The possible 
explanation for this might be the fact that as the age increases, the complications 
of chronic kidney disease that affects multiple organ systems of the body 
increases leading to decreased functional capability of the patients. 
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There was mild over-representation of male gender in the sample which was 
comparable to other studies but there was no differences noted in QOL scores. 
However in a study conducted by Sathvik et al,18 lower scores were observed in 
female patients. 
Higher QOL scores were observed in employed patients and patients with 
higher annual income in all 4 domains and reaches statistical significance in the 
psychological health domain. The findings of our study are consistent those of 
the other studies.17, 18 The probable reasons for this might be financial 
independence, better mobility and lesser restriction of daily activities. But 
around 80% of the patients in our study were unemployed. So employment has 
been found to be an important factor improving the QOL in ESRD patients.55 
Higher income increases the ability of the patient to afford the necessary 
treatment and increases compliance with the prescribed medicines. 
There was no significant differences in QOL between the groups divided based 
on educational and marital status. We expect a better QOL scores in the patients 
on thrice weekly hemodialysis. Interestingly we noticed comparable QOL 
scores in patients on twice weekly and thrice weekly hemodialysis. The possible 
reason for this observation is selection of patients for thrice weekly sessions. 
Though we advice the patients for thrice weekly schedule, patients usually 
prefer twice weekly schedule unless they are overtly symptomatic (volume 
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overload). So patient selection for thrice weekly schedules might be the 
contributing factor for non-superiority of QOL in thrice weekly patients. 
Patients who were on dialysis for a longer period (dialysis vintage) responded 
with lower QOL scores and there was a negative correlation noted in all 4 
domains. Similar observations were made in the past studies.41 The possible 
reasons for this observation might be the association of longer vintage with 
unfavorable changes in nutritional status like body weight and composition, 
higher risk of access failures and cardiovascular morbidity. In a study conducted 
by chertow et al, even a year longer the dialysis vintage was shown to be 
associated with 6% increase in the risk of death.20 However in a study 
conducted by veerappan et al, longer dialysis vintage was shown to be a positive 
predictor of QOL.3  
We observed lower QOL scores in the patient group with longer travel time 
when compared with shorter travel time. In an international study conducted by 
moist et al, longer travel time was shown to be significantly associated with 
decreased QOL and greater mortality.42 The reason might be the financial 
expenses faced by the patient associated with longer travel time. So the patients 
with travel time longer than 60 minutes have to be identified and measures to 
decrease the travel time should be undertaken. This problem could be overcome 
only by encouraging alternative renal replacement therapy in the form of 
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peritoneal dialysis in eligible patients and the development of standalone 
satellite dialysis centres as it is there in the western world.42 
Correlation with clinical characteristics 
Higher albumin levels were associated with better quality of life as reflected by 
better QOL scores in all 4 domains that are significant in psychological health 
domain  (p< 0.05) and also showed a significant positive correlation by Pearson 
correlation test in the physical health domain (p< 0.01). Similar observations 
were made in many previous studies.3, 17, 18. The mean estimated protein intake 
in our patients is 1.54 ± 0.60 as calculated by PNA and the mean albumin level 
in our patients was 4.06± 0.41. There are various markers of malnutrition in 
CKD population, but as of the present date serum albumin level is the marker 
that was widely studied and considered to be a useful marker of malnutrition.   
This underscores the importance of correction of albumin to prevent 
malnutrition and increase the QOL. So hypoalbuminemia (serum albumin < 3.5 
gm/dl) can be considered as a marker of malnutrition and measures to prevent 
and treat the condition by good dietary counseling of the patients might improve 
their QOL.  
Our study shows that there was a high prevalence of anemia in our setting. The 
main reason for such high prevalence of anemia is the financial constraints of 
the patients making them unaffordable to the cost of erythropoietin. Patients 
with higher hemoglobin levels had better QOL and there was positive 
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correlation of hemoglobin with the QOL but this correlation did not reach 
statistical significance. Similar observations were made in the past.3, 17, 18 There 
was a high prevalence of functional iron deficiency in our population. In the 
subgroup analysis of patients divided based on their iron status (absolute iron 
deficiency and functional iron deficiency) and erythropoietin use, there was no 
difference in QOL scores noted between the groups.  
Patients who were treated with EPO had comparable scores with patients who 
were not on EPO. But of those patients who received erythropoietin, there was a 
statistically significant positive correlation between the higher doses of EPO 
and better QOL in the physical health domain and total QOL (p< 0.05). The 
correlation persisted even after adjusting for their hemoglobin levels. So the 
beneficial effect of EPO does not solely depend on the increment in hemoglobin 
levels of the patient. In a study conducted by Canadian erythropoietin study 
group, it was shown that the patients treated with EPO were less fatigued, and 
had better exercise tolerance compared with the placebo, but the benefit was 
concluded to be secondary to increment in hemoglobin levels.19 In a study 
conducted by Beusterien et al, it was concluded that in addition to improvement 
in hematocrit levels other unidentified factors also contributes for the better 
QOL outcomes.59 
We noticed a high prevalence rate of native arteriovenous fistula in around 90% 
of the population. However, we have not found any significant differences in 
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the groups pertaining to the access. But studies in the past had shown that 
patients with catheter as access had lower QOL.3,17,37 The reason for absence of 
such finding in our study might be the very small number of patients with 
current catheter use. 
We were able to achieve a spKt/V of greater than 1.2 in only 50% of the 
patients but there was no difference in QOL between the groups with greater or 
lesser spKt/V. Some observational studies in the past have shown an association 
between higher Kt/V with lower risk of mortality. However in a landmark trial 
of Dialysis Outcomes and Practice Patterns Study (DOPPS) there was no 
benefit in QOL and in fact a lower QOL was seen with higher dialysis dose.17 
Patients with chronic hepatitis B had lower QOL in comparison with chronic 
hepatitis C and seronegative patients but the difference was not significant. In a 
study conducted by Ong et al in general population, patients with chronic 
hepatitis B infection had poorer QOL compared with the placebo particularly 
when they experience disease progression. Patients on MHD with chronic 
hepatitis C have been shown to have lower QOL in a study by Afsar et al.44 So 
measures to prevent seroconversion  has to be undertaken to  prevent 
deterioration of the QOL in patients on MHD. 
No other significant association or correlation were noted in relation to the 
patient related factors like co-morbidities, native kidney disease, calcium levels, 
phosphorus level, and calcium-phosphorus product.  
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SUMMARY AND CONCLUSION 
 
One hundred and five patients on maintenance hemodialysis in our centre were 
cross-sectionally included in the study. The Quality of life of patients was 
assessed with WHOQOL BREF scale. The same was correlated with 
demographic and clinical variables of the patients. 
Observations made out of the study 
By independent t test or ANOVA, unemployment status, lower economic status, 
longer dialysis vintage and longer travel time to the dialysis centre were the 
demographic factors associated with  poorer  QOL and lower albumin and 
hemoglobin levels were  the clinical factors associated with  poorer  QOL. 
There was no difference in QOL based on the analysis done with iron status of 
the patient. But higher doses of erythropoietin were associated with better QOL 
in these patients. 
By pearson or spearman’s rank correlation test, higher age was negatively 
correlated with QOL and higher albumin level, higher hemoglobin levels and 
higher doses of erythropoietin use were positively correlated with QOL scores. 
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Limitations of the study 
As the present study was a cross sectional study, drawing cause and effect 
conclusion between the factors and QOL is not possible. The other limitation of 
the present study is small sample size and the study was conducted in a single 
centre – so the result obtained in the present study may not be generalizable to 
other patient population. Most of the patients in our study were on twice weekly 
dialysis schedule. Dialysis inadequacy might be a confounding factor for low 
QOL observed. This also makes it difficult to compare with other studies with 
patients on thrice weekly schedule. The other important confounding factor is 
the fact that the study was carried out in the same centre where the authors 
worked and this might led on to biased scoring of the questionnaire. Since the 
questionnaire was a self administered one, fluctuations in the patient’s attention, 
motivation, comprehension might have influenced the scores – leading on to 
measurement error.60 
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Conclusion 
Our results show that higher age and unemployment of the demographic factors 
and hypoalbuminemia of the clinical factors were the significant negative 
determinants of QOL. Higher doses of erythropoietin were the significant 
positive determinant of QOL. The results of this study suggest that the QOL in 
patients on MHD is considerably influenced by the factors like demographic 
parameters, clinical and laboratory parameters of the patient. Of these 
parameters, many parameters are modifiable and the steps to prevent or treat 
such factors might improve the QOL in the patients. 
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 ANNEXURE 1 - ABBREVIATIONS 
1. CKD – Chronic kidney disease 
2. CKD5  – Chronic kidney disease stage 5 
3. ESRD – End stage renal disease 
4. MHD –Maintenance Hemodialysis 
5. QOL – Quality of life 
6. spKt/V – Single pool kt/V 
7. e Kt/V – equilibrated kt/V 
8. KDOQI  - Kidney Disease Outcomes Quality Initiative 
9. KDIGO  - Kidney Disease: Improving Global Outcomes 
10. TSAT – Transferrin saturation 
11. TIBC – Total Iron binding capacity 
12. nPNA - normalized protein nitrogen appearance 
13. nPCR  - normalized protein catabolic rate 
14. Pre-BUN – Predialysis Blood Urea nitrogen 
15. Ca  - serum calcium 
16. Pi  - serum phosphorus 
17. PTH – parathormone 
18. Ca-P product –Calcium phosphorus product 
19. HCV – Hepatitis C Virus 
20. HBV – Hepatitis B Virus 
21. DOPPS - Dialysis Outcomes and Practice Patterns Study  
 ANNEXURE 3  
 PROFORMA FOR THE STUDY OF DETERMINANTS OF QUALITY 
OF LIFE IN HAEMODIALYSIS PATIENTS 
                                     
PATIENT NAME:     OP NUMBER 
S. NO Variables  
1 Age  
2 Gender  
3 Educational status  
4 Marital status  
5 Annual Income – family  
6 Annual Income  - Patient  
7 Employment   
8 Duration of dialysis in months   
9 Time taken to reach the centre in mts  
10 Number of times of dialysis weekly  
11 Hemoglobin level in gms %  
12 Serum Creatinine – mg/dl  
13 Blood Urea – mg/dl  
14 Serum Albumin mg/ dl  
15 Native kidney disease  
16 
Comorbidities: 
a) Diabetes Mellitus (Yes/ No) 
b) Hypertension (Yes/ No) 
c) Hypertension (Yes/ No) 
d) IHD (Yes/ No) 
 
 
 
 ANNEXURE 3  
 PROFORMA FOR THE STUDY OF DETERMINANTS OF QUALITY 
OF LIFE IN HAEMODIALYSIS PATIENTS 
…….Contd 
17 
Serology 
a) Hepatitis B (Yes/ No) 
b) Hepatitis C (Yes/ No) 
 
18 Calcium in mg/dl  
19 Phosphorus mg/ dl  
20 Calcium Phosphorus product   
21 PTH   in pg/ml  
22 Type of access of HD (Fistula/ Catheter)  
23 On Erythropoietin (Yes/ No)  
24 Erythropoietin dose / week  
25 Serum Ferritin (micro gm/ L)  
26 Serum Iron  
27 Serum TIBC   
28 Post dialytic weight & UF Volume  
29 Urinary Urea nitrogen   
30 Urinary Creatinine Clearance   
31 Calculated protein nitrogen appearance (nPNA)  
 
  
 ANNEXURE 4 - WHOQOL BREF SCALE – TAMIL VERSION 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
Patients’ Signature: 
Date:
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U 
BALASUBRAMA
NI 
O100334
04 1 
2.5
7 
1
1 
1
1 
1
3 
1
5 50 50 M 4 M N 
6000
0 21 15min 4 
8.
5 299 
17.
3 DN DM/SHT N 9.5 2.21 21 
8.4
5 4.1 F N 
NATARAJAN 
O030233
28 1.1 
1.7
6 
1
2 9 9 9 39 70 M 
DIPLO
MA M N 
7200
0 79 3hr 2 
9.
6 902 
58.
3 DN 
DM/SHT/
IHD N 9.3 3.1 
28.
83 
5.7
4 3.3 F 
8000
U 
GAYATHRI 
O100990
13 1.4 
1.2
1 
1
4 
1
0 
1
2 
1
5 51 26 F 12 N N 
1780
00 14 3hr 2 
8.
4 337 
38.
2 NK SHT N 8.2 4.7 
38.
54 
12.
5 4.3 F 4000/ 
VALLIAMMAL 
O090107
67 1.7 
1.1
6 
1
2 
1
5 
1
6 
1
1 54 51 F N M N NIL 36 
2hr 
30min 2 
8.
8 63 
20.
9 NK SHT N 8.8 6.5 
57.
2 
8.9
8 4.2 F 
8000
U 
ARUSAMY 
O060086
19 1.1 
1.3
1 
1
2 
1
0 8 
1
1 41 65 M 
DIPLO
MA M N 
3000
00 71 
1hr30m
in 2 
8.
4 770 
19.
9 NK SHT N 9.3 3.4 
31.
62 
13.
1 4.7 F 
8000
U 
NOUFIYA 
O100083
64 1.1 
1.1
3 
1
3 
1
1 
1
6 
1
5 55 29 F 10 M N 
1000
00 22 
2hr 
30min 2 
7.
6 974 
19.
2 NK SHT N 8.4 4.4 
36.
96 
10.
9 4.2 F 
8000
U 
NATRAJ 
O100638
45 2.3 
1.6
1 
1
3 
1
1 
1
6 
1
5 55 56 M 7 M E 
1340
00 5 
1hr30m
in 2 
8.
5 337 N GN N N 8.6 7.1 
61.
06 
6.0
9 3.7 C 
4000
U 
SEKAR 
O080252
40 1 
1.1
3 
1
1 
1
1 
1
6 
1
4 52 50 M 6 M E 
9600
0 5 20min 2 
6.
9 410 
21.
8 DN DM/SHT N 9.9 7.8 
77.
22 
9.3
8 3.7 F 
4000
U 
PRATHAP 
CHANDAR 
O110429
72 1.2 1.2 
1
1 
1
1 
1
9 
1
6 57 50 M BSc M E 
5000
0 7 2hr 2 
8.
5 297 
24.
4 NK SHT N 9.2 4.8 
44.
16 13 4.1 F 
8000
U 
PERUMALSAMY 
O090905
13 1.1 
1.2
8 9 9 
1
1 
1
4 43 67 M 6 M N 
8400
0 40 
1hr30m
in 2 
5.
2 192 
19.
9 DN DM/SHT N 8.5 6.3 
53.
55 
16.
5 3.8 F 
4000
U 
SIVARAJ 
O090321
05 1.4 
1.3
9 9 4 4 8 25 63 M BA M N 
7200
0 33 1hr 3 
6.
4 628 
31.
8 DN DM/SHT N 8.9 5.5 
48.
95 7.8 4.2 F 
4000
U 
 Name Opno. 
Kt
/v 
nP
CR 
D 
1 
D 
2 
D 
3 
D  
4 
Tot
al 
QO
L 
Ag
e 
gend
er 
educat
ion  
Mari
tal  
Employ
ment  
Inco
me 
Durati
on Time 
No
./ 
wk 
H
b 
Ferri
tin 
TS
AT NKD  
DM/SHT
/IHD 
Serol
ogy Y 
/ N / 
B /C Ca Pi 
Ca 
X P 
Cre
at 
Albu
min 
Acce
ss  
Eryth
ro 
dose 
SENTURAPANDI
YAN 
O060379
76 1.1 1.2 
1
1 
1
1 
1
2 
1
1 45 72 M 3 M N 
1200
0 42 45min 3 
6.
7 484 
13.
7 DN 
DM/SHT/
IHD N 9 5 45 
8.9
1 3.9 C N 
SANDEEP 
O110383
21 0.8 
1.3
9 
1
2 
1
1 
1
1 
1
1 45 24 M 
DIPLO
MA N E 
1200
00 7 30min 3 
6.
8 158 
11.
9 GN SHT N 8.2 5.7 
46.
74 
8.0
1 3.9 F N 
DHANDAPANI 
O110584
56 0.7 
0.8
4 
1
1 
1
2 
1
3 
1
4 50 63 M 10 M N 
4800
0 5 30min 3 9 118 
8.2
8 DN DM/SHT N 8.3 4 
33.
2 
7.4
3 4.1 F 
4000
U 
MANOHARAN 
O090187
65 1 
0.9
9 
1
0 
1
0 
1
3 
1
6 49 50 M 9 M N 
4800
0 34 
2hr30m
in 2 
6.
7 163 
19.
1 NK SHT/IHD N 8.9 11.1 
98.
79 7.5 3.7 F N 
SAMPATHKUMA
R 
O100948
08 1.1 
1.2
6 
1
2 
1
2 
1
1 
1
3 48 48 M 12 M N 
4000
0 14 2hr 2 
6.
4 843 
58.
1 NK SHT N 10 3.5 
36.
4 
15.
5 4.3 F N 
AMBIKA 
O080333
88 0.9 
0.1
6 
1
2 
1
1 
1
5 
1
2 50 52 F 8 M N 
5000
0 44 
1hr30m
in 2 
1
1 435 
16.
9 DN 
DM/SHT/
IHD N 9.5 7.3 
69.
35 8.2 4.7 F 
8000
U 
PAUL 
O070549
79 1 
3.4
3 
1
1 
1
3 
1
5 
1
3 52 60 M 9 M E 
1000
00 61 1hr 3 
6.
6 784 
19.
7 DN DM/SHT N 9 6.4 
57.
6 
11.
6 4.2 F 
4000
U 
DHANAPAL 
O070498
59 0.9 
2.9
8 
1
1 
1
3 
1
2 
1
5 51 36 M 
DIPLO
MA N E 
1500
00 53 30min 3 
9.
5 133 
16.
2 DN DM/SHT N 8.5 7 
59.
5 
8.1
1 3.6 F 
4000
U 
JAGANATHAN 
O100307
31 1.3 
2.6
3 
1
1 
1
2 9 
1
0 42 45 M 10 M N 
8700
0 21 1hr 3 
7.
2 257 14 DN DM/SHT N 8.9 4.1 
36.
49 
17.
7 4.7 F 
8000
U 
DHANABAKIYA
M 
O100524
90 0.9 1.4 
1
0 9 
1
6 
1
5 50 34 F 5 M N 
6000
0 9 
3hr30m
in 2 
7.
4 1.6 
12.
5 NK SHT N 8.5 4.5 
38.
25 
8.9
5 3.8 F N 
THANGAVEL 
O110771
08 0.9 
0.9
5 
1
1 
1
0 9 
1
2 42 45 M 5 M N 
7200
0 4 
2hr15m
in 2 
8.
6 210 
24.
9 
ADP
KD NIL N 8.5 5.6 
47.
6 
9.7
6 3.9 C 
4000
U 
SAVITHIRI 
O080028
80 1.8 
1.6
8 
1
1 9 
1
3 
1
6 49 52 F 8 M N 
6000
0 6 2hr 2 
6.
9 507 
22.
2 NK SHT N 9.7 5.83 
56.
55 
9.4
4 4.3 F 
8000
U 
UMACHANDRA
N 
O110655
88 1 
0.9
6 
1
4 
1
4 
1
5 
1
3 56 45 M 8 M N NIL 6 30min 2 
9.
8 496 68 DN DM/SHT N 8.7 4.1 
35.
67 
10.
5 4.2 C 
4000
U 
SARASWATHI 
O070165
65 1.7 
1.6
3 
1
1 
1
0 
1
3 
1
2 46 48 F 8 M N 
3400
0 72 2hr 2 
6.
6 ## 
26.
9 NK SHT N 8.4 6.4 
53.
76 
9.4
8 4 F 
1000
U 
GOVINDAMMAL 
O070021
62 1.6 
1.5
9 
1
1 
1
0 
1
6 
1
1 48 57 F NK M N 
9600
0 57 
1hr30m
in 2 
5.
9 179 35 NK SHT N 8.4 3.88 
32.
44 
8.9
1 4.2 F N 
LAWRANCE 
O100291
40 1.1 1.7 
1
3 
1
3 
1
5 
1
3 54 29 M 10 M E 
7200
0 21 20min 3 
5.
6 103 16 NK SHT N 8.9 5.2 
46.
28 
11.
4 4.5 F 
6000
U 
JACOB 
O100419
25 1.2 
0.9
8 
1
1 
1
1 
1
6 
1
2 50 36 M 10 N N 
9600
0 9 5hr 2 
7.
4 274 N GN SHT N 9.9 6.2 
61.
38 
9.6
6 4.1 F 
4000
U 
USHA 
O090225
79 1.2 
0.9
6 9 9 
1
2 
1
5 45 36 F 12 M N 
6000
0 34 45min 2 
8.
3 628 
21.
8 NK SHT N 7.5 6.1 
45.
75 
8.3
3 3 F 
4000
U 
VASANTHI 
O110163
97 1 
2.0
7 9 8 
1
1 
1
0 36 43 F 12 M N 
3600
0 9 3hr 3 
5.
8 297 N GN SHT N 9.4 4.5 
42.
3 
8.9
9 3.9 C 
6000
U 
MEENACHISUN
DARAM 
O100115
58 1.3 
1.1
4 9 
1
3 
1
3 
1
6 51 53 M BE M N 
2400
00 23 30min 3 
9.
4 691 
25.
4 DN DM/SHT N 7.4 5.1 
37.
74 
5.9
8 3.6 F 
8000
U 
JAYARAJ 
O080085
76 1.2 
1.2
8 9 
1
1 5 
1
3 38 72 M 8 N N NIL 36 45min 2 8 666 
21.
6 DN DM/SHT N 6.5 9.2 
59.
8 
11.
8 4.3 F N 
 Name Opno. 
Kt
/v 
nP
CR 
D 
1 
D 
2 
D 
3 
D  
4 
Tot
al 
QO
L 
Ag
e 
gend
er 
educat
ion  
Mari
tal  
Employ
ment  
Inco
me 
Durati
on Time 
No
./ 
wk 
H
b 
Ferri
tin 
TS
AT NKD  
DM/SHT
/IHD 
Serol
ogy Y 
/ N / 
B /C A Pi 
Ca 
X P 
Cre
at 
Albu
min 
Acce
ss  
Eryth
ro 
dose 
DHAMODHARA
N 
O100272
82 1.2 
1.2
6 
1
1 
1
1 
1
1 
1
1 44 32 M ME N N 
1400
00 17 10min 2 
9.
1 674 
30.
9 NK SHT N 9.2 3 
27.
6 
10.
5 4.3 F 
4000
U 
KANCHANA 
O100638
27 1.5 
1.3
9 
1
2 
1
3 
1
1 
1
2 48 62 F 10 M N 
6000
0 18 20min 2 
8.
5 451 
34.
6 DN DM/SHT N 10 3.4 
34.
34 
7.3
8 3.8 F 
4000
U 
VIJAYAKUMAR 
O090171
21 1.2 
1.2
3 
1
2 
1
1 
1
3 
1
6 52 49 M 5 M N 
1200
00 24 30min 2 
8.
7 50 
27.
4 DN DM/SHT N 6.4 6.4 
40.
96 
15.
5 4.3 F N 
SELVARAJ 
O100236
27 0.8 
1.0
4 
1
0 9 7 9 35 30 M 7 N N 
2400
0 42 3hr 2 
7.
6 468 
35.
5 NK SHT N 8.4 3.6 
30.
24 
13.
3 4.8 F 
4000
U 
MEGANATHAN 
O080359
15 1.3 
1.4
8 
1
3 
1
3 
1
6 
1
0 52 33 M 9 M E 
7200
0 44 
1hr15m
in 2 
6.
4 125 
15.
1 NK SHT N 6.5 5.6 
36.
4 
13.
7 4.1 F 
4000
U 
SEKAR 
O110360
38 1.1 
0.7
8 
1
1 9 
1
3 
1
2 45 55 M N M N 
4800
0 8 3hr 2 
6.
9 285 
26.
2 GN SHT N 8.8 4.2 
36.
96 
7.3
5 4.6 F 
1000
U 
MADHANAGOP
AL 
O050319
96 1 
1.3
2 9 
1
1 5 
1
1 36 55 M 10 M N 
4500
0 34 
2hr30m
in 2 
5.
3 459 22 DN DM/SHT N 6.5 5.2 
33.
8 
8.2
5 4 F 
4000
U 
SUSEELA 
O110240
96 1.4 
1.1
7 
1
2 
1
0 
1
6 
1
3 51 28 F 12 M N 
4800
0 10 45min 2 
7.
8 584 
39.
7 NK SHT N 8.3 6.7 
55.
61 
6.4
3 3.8 F 
8000
U 
VENKATAPATHY 
O070509
39 0.9 
0.9
1 
1
3 
1
1 
1
6 
1
5 55 56 M 10 M N 
1000
00 27 10min 2 
6.
9 17 
11.
6 DN 
DM/SHT/
IHD N 7.7 6.7 
51.
59 
13.
8 4.1 F 
8000
U 
SIVASHANMUG
AM 
O060390
21 0.9 
1.0
4 
1
3 
1
2 9 
1
1 45 52 M 10 M E 
1200
00 6 30min 2 
8.
9 225 31 DN DM/SHT N 8.2 4 
32.
8 
7.4
9 3.5 C N 
Mr. 
Ranganayagam 
O090038
25 1.2 
2.3
9 
1
0 8 
1
2 
1
1 41 71 M M.A M N 
200,0
00 31 30min 3 
7.
5 503 
21.
3 DN 
DM/SHT/
IHD N 7.7 1.4 
10.
78 
8.1
1 3.8 F 
4000 
U 
Ms. Indharani 
O091059
66 1.4 
1.3
2 
1
4 
1
2 
1
1 
1
2 49 27 F 12 N N 
120,0
00 25 15min 2 
7.
7 317 
27.
3 
not 
kno
wn SHT N 8.3 5.73 
47.
73 
11.
4 4 F 
8000 
U 
Mrs. 
Vijayabharathi  
O090333
31 1.4 
1.2
7 
1
5 
1
1 
1
6 
1
7 59 45 F 10 M N 
8000
0 3 30min 2 6 132 
20.
3 GN SHT N 8.3 6.7 
55.
61 
10.
4 4 F 
1200
0U 
Mr. Murali Rao 
O110729
26 1 
1.1
4 
1
4 
1
2 
1
6 
1
2 54 42 M 10 M N 
2400
0 3 2hrs 2 7 397 
18.
6 DN SHT/DM N 8.1 4.2 
34.
02 
7.2
4 3.9 C 
4000
U 
Mrs. Selvi  
O110485
80 1.2 
1.8
8 
1
5 
1
7 
1
6 
1
4 62 47 F 10 M N 
8400
0 6 45min 3 
1
1 123 
18.
1 
not 
kno
wn SHT N 7.8 9.9 
77.
22 
5.9
5 3.6 F 
8000 
U 
Mrs. 
Dhanalakshmi 
O110209
18 0.7 
1.0
2 
1
2 
1
4 
1
5 
1
3 54 42 F 0 M N 
1200
00 10 1hr 2 
6.
8 163 
20.
3 
not 
kno
wn SHT N 8.3 3.7 
30.
71 
11.
2 4.2 F 
8000 
U 
Mr. Natarajan 
O060440
06 0.9 
2.3
3 9 7 5 5 26 55 M 10 M N 
1200
00 51 30min 3 
6.
1 19 
6.6
2 
not 
kno
wn SHT N 9.2 7.3 
67.
16 
8.3
3 4.2 F 
8000 
U 
Mr. Rangasamy 
O030290
65 
 
 0.9 
2.2
4 
1
4 
1
4 
1
5 
1
6 59 78 M 5 M N 
1000
0 4 30min 3 7 115 
13.
9 
not 
kno
wn 
SHT/IH
D N 9.3 5.5 
51.
15 
8.1
2 4.1 F 
8000
U 
 Name Opno. 
Kt
/v 
nP
CR 
D 
1 
D 
2 
D 
3 
D  
4 
Tot
al 
QO
L 
Ag
e 
gend
er 
educat
ion  
Mari
tal  
Employ
ment  
Inco
me 
Durati
on Time 
No
./ 
wk 
H
b 
Ferri
tin 
TS
AT NKD  
DM/SHT
/IHD 
Serol
ogy Y 
/ N / 
B /C Ca Pi 
Ca 
X P 
Cre
at 
Albu
min 
Acce
ss  
Eryth
ro 
dose 
Mr. 
Shanthappan 
O110204
52 1.1 
2.7
5 9 
1
2 
1
6 
1
3 50 50 M 0 M N 
3600
0 10 
1hr30
min 3 
9.
5 178 
20.
1 GN SHT N 8.3 8.3 
68.
89 
11.
6 3.6 F 
8000
U 
Mr. 
Natchimuthu 
O090166
47 3.3 
2.6
2 
1
3 
1
2 9 
1
3 47 62 M 0 M N 
1000
0 8 2hrs 3 
8.
8 194 
22.
9 
not 
kno
wn SHT N 8.9 6.2 
55.
18 14 4.6 F 
8000
U 
Mr. 
Shanmugam 
O100326
81 1.5 
2.3
3 
1
1 9 
1
1 
1
0 41 39 M 10 M E 
2000
00 13 20min 3 
1
4 241 29 
not 
kno
wn SHT N 8.3 4.9 
40.
67 
13.
4 4.4 F 
8000
U 
Mrs. Abibunisha 
O090827
13 1.3 
0.8
6 
1
1 
1
3 
1
1 
1
1 46 60 F 5 M N 
4000
0 21 15min 2 
8.
6 69 
15.
3 
not 
kno
wn SHT N 8.3 3.3 
27.
39 
8.6
6 3.7 F 
2000
U 
Mrs. 
Vennilamani 
O060130
49 1.3 
1.3
5 
1
1 
1
1 8 
1
2 42 64 F 8 M N 
1000
0 63 1hr 2 
5.
8 951 
15.
2 
not 
kno
wn SHT N 9.9 6.9 
68.
31 
13.
4 4.4 F N 
Mrs. 
Kannammal 
O08039
153 1.1 1.3 
1
0 9 
1
1 
1
2 42 52 F 4 M N 
4000
0 42 
1hr30
min 2 
4.
7 
>20
00 N GN 
SHT/IH
D N 9.4 6.9 
64.
86 
6.9
5 3.8 F 
6000
U 
Mr. Jawahar 
O10043
985 1.5 
0.9
1 
1
0 
1
1 
1
5 
1
2 48 42 M BA M E 
8000
0 17 
4hrs15
min 2 
8.
8 162 
21.
2 
othe
rs SHT N 9.1 5.3 
48.
23 6.9 3.5 F 
2000
U 
Mr. 
Chinnappan 
O11027
109 1.1 1 
1
5 
1
3 
1
6 
1
5 59 60 M 7 M N 
2400
00 9 30min 2 
6.
2 157 
31.
1 PKD SHT N 8.8 3.4 
29.
92 
5.4
6 4.1 F 
4000
U 
Mr. 
Selvakumar 
O09069
652 1.1 
1.6
1 
1
3 
1
6 
1
7 
1
4 60 23 M 9 M E 
3600
0 3 4hrs 2 
6.
1 426 
9.9
6 
not 
kno
wn SHT N 7.9 9 
71.
1 14 4.3 C N 
Mr. Shankar 
O12051
336 0.5 
0.6
8 
1
3 
1
1 
1
6 
1
3 53 34 M 6 M N 
1000
00 6 1hr 2 
6.
1 449 
16.
8 
not 
kno
wn SHT N 8.9 5.9 
52.
51 
10.
3 3.8 F 
8000
U 
Mr. 
Velmurugan 
O10021
341 1.3 
1.5
7 
1
8 
1
8 
1
6 
1
3 65 34 M 8 M N 
3000
0 17 
1hr30
min 3 
5.
9 539 
41.
5 
not 
kno
wn SHT N 8.6 6.5 
55.
9 
11.
9 4.2 F N 
Mrs. 
Jagathambal 
O10090
239 1.6 
1.3
2 
1
1 
1
0 
1
5 
1
1 47 47 F 7 M N 
1800
00 14 
1hr 
30min 2 
9.
1 340 
20.
7 GN SHT N 8.6 3.4 
29.
24 
10.
1 3.9 F 
4000
U 
Mr. 
Murugesan 
O09055
314 1.2 
1.0
6 
1
0 
1
2 5 
1
0 37 44 M 12 M N 
4000
0 4 
2hr30
min 2 
8.
1 417 
26.
9 DN SHT/DM N 8.8 6.5 
57.
2 
9.8
9 4 F N 
Mrs. 
Mahalakshmi 
O10068
865 1.1 1.8 
1
3 
1
3 9 
1
3 48 41 F 10 M N 
5000
0 17 
1hr30
min 3 
7.
8 327 N GN SHT N 8.7 4 
34.
8 
9.0
3 4.1 F N 
Mrs. Selvi  
O11003
724 1.6 
1.1
6 
1
0 
1
0 9 9 38 51 F 8 M N 
1500
0 12 
1hr30
min 2 
7.
9 234 N GN SHT N 9 6.6 
59.
4 
8.6
9 3.2 F 
8000
U 
Mrs. 
Saraswathi 
 
 
 
O07011
450 1.6 
1.6
5 
1
0 
1
1 9 
1
2 42 57 F 5 M E 
6000
0 32 1hr 2 
1
0 501 
37.
1 
not 
kno
wn SHT N 8.7 4.7 
40.
89 
9.6
9 4.2 F 
4000
U 
 Name Opno. 
Kt
/v 
nP
CR 
D 
1 
D 
2 
D 
3 
D  
4 
Tot
al 
QO
L 
Ag
e 
gend
er 
educat
ion  
Mari
tal  
Employ
ment  
Inco
me 
Durati
on Time 
No
./ 
wk 
H
b 
Ferri
tin 
TS
AT NKD  
DM/SHT
/IHD 
Serol
ogy Y 
/ N / 
B /C Ca Pi 
Ca 
X P 
Cre
at 
Albu
min 
Acce
ss  
Eryth
ro 
dose 
Mrs. 
Azhagusundar
avalli 
O06041
249 1 
0.8
2 
1
1 
1
1 
1
3 
1
4 49 61 F MBBS M N 
3000
00 64 
1h15mi
n 2 
6.
5 802 
20.
8 DN SHT/DM N 9.3 2.5 
23.
25 
7.8
3 4.1 F 
8000
U 
Mr. 
Thangavelu 
O10048
562 1.3 
0.7
3 
1
2 
1
0 9 
1
0 41 29 M 12 M N 
7000
0 20 45min 2 
9.
6 178 26 
not 
kno
wn SHT N 9.7 5.9 
57.
23 
3.4
8 4.7 F N 
Mr. Mohan  
O09028
323 1 
1.2
3 
1
1 
1
1 
1
1 
1
2 45 50 M 8 M E 
7200
0 34 30min 3 
8.
3 276 
22.
7 
not 
kno
wn SHT N 9 6.7 
60.
3 
8.6
8 4.5 F 
4000
U 
Mr. Arumugam  
O09091
704 1.4 
1.3
5 
1
4 
1
4 
1
2 
1
3 53 51 M 6 M E 
6000
0 26 2hrs 2 
1
2 1175 
25.
9 
not 
kno
wn SHT N 7.9 7.5 
59.
25 
15.
4 4.6 F 
4000
U 
Mrs. 
Saraswathi 
O10095
529 1.6 
1.5
3 
1
1 9 7 
1
0 37 51 F 4 M N 
7200
0 14 3hrs 2 
6.
9 427 
26.
4 
not 
kno
wn SHT N 9 8.8 
79.
2 
13.
6 4.1 F 
2000
U 
Mrs. Poongodi 
O10024
744 1.4 
1.6
2 
1
0 
1
3 
1
3 
1
4 50 34 F 10 M N 
5000
0 22 3hrs 2 7 323 
18.
5 
not 
kno
wn SHT N 8.1 4.4 
35.
64 
13.
9 4.2 F N 
Mr. Samy 
Thangavel 
O07033
203 1.2 
1.3
3 
1
1 
1
2 
1
5 
1
3 51 59 M 10 M N 
1200
00 19 4hrs 2 
8.
2 98 11 DN SHT/DM N 8.2 6.8 
55.
76 
8.6
8 4.5 F N 
Mrs. 
Shanthamani 
O07013
234 0.6 
1.9
8 
1
4 
1
4 
1
6 
1
5 59 56 F 10 M N 
1000
00 58 10min 3 
7.
5 982 45 
not 
kno
wn SHT N 5.4 9.2 
49.
68 
12.
5 3.9 F N 
Mr. V. 
Arumugam 
O10017
630 0.9 
2.2
2 9 
1
2 9 9 39 36 M 10 M N 
5000
0 16 
2hrs30
min 3 
8.
9 45 
6.5
2 
not 
kno
wn SHT N 8.7 6.5 
56.
55 
7.4
7 3.9 F 
8000
U 
Mr. 
Sudhakaran 
O08067
124 1.3 
1.4
3 
1
1 
1
3 9 
1
4 47 54 M BA N N 9600 40 45min 3 
1
1 669 
32.
7 
not 
kno
wn 
SHT/IH
D N 9.1 4.3 
39.
13 
9.0
8 4.5 F 
4000
U 
Mrs. Selvi  
O97035
661 1.5 
1.3
8 
1
3 
1
1 
1
2 
1
4 50 40 F 7 M N 
6000
0 174 30min 2 
1
3 
>20
00 N 
not 
kno
wn SHT B 9.1 5.4 
49.
14 
8.1
8 2.9 F 
4000
U 
Mr. 
Ravichandran 
O11053
263 1.1 
2.4
2 
1
3 9 7 8 37 36 M 2 M N 
1500
0 6 20min 3 
7.
7 980 N DN SHT/DM B 9.2 4.3 
39.
56 
11.
8 4.5 F 
8000
U 
Mr. 
Sundaramoort
hy 
O09088
384 1.5 
2.3
9 
1
4 
1
2 
1
5 
1
1 52 36 M CLIS M E 
1200
00 22 2hrs 3 
7.
5 ## N 
not 
kno
wn SHT B 6.3 3.5 
22.
05 11 4.4 F 
8000
U 
Mr. Arumugam 
VR 
O09056
246 1.4 
2.2
2 4 7 9 
1
1 31 51 M 9 M N 
3360
0 30 2hrs 3 
7.
3 36 N 
not 
kno
wn SHT B 7.4 4.6 
34.
04 
7.7
4 3.4 F 
2000
U 
Mr. Saleem 
basha 
O11071
940 0.9 
0.9
8 
1
1 
1
2 
1
1 
1
0 44 33 M BA M N 
1000
00 12 
2hrs30
min 2 
6.
1 877 N DN SHT/DM B 4.6 8.9 
40.
94 
8.0
5 3.8 F 
8000
U 
 Name Opno. 
Kt
/v 
nP
CR 
D 
1 
D 
2 
D 
3 
D  
4 
Tot
al 
QO
L 
Ag
e 
gend
er 
educat
ion  
Mari
tal  
Employ
ment  
Inco
me 
Durati
on Time 
No
./ 
wk 
H
b 
Ferri
tin 
TS
AT NKD  
DM/SHT
/IHD 
Serol
ogy Y 
/ N / 
B /C Ca PI 
Ca 
X P 
Cre
at 
Albu
min 
Acce
ss  
Eryth
ro 
dose 
Mr.Govindhara
j 
O10097
415 1.1 
1.0
7 
1
0 
1
2 
1
2 
1
1 45 55 M 10 M N 
3600
0 12 30min 2 9 125 N DN SHT/DM B 8.8 5.7 
50.
16 8.2 4.2 F 
8000
U 
Mr. 
Chinnasamy 
O07060
273 2 
1.1
5 
1
2 
1
3 
1
2 
1
4 51 61 M 5 M E 
1000
0 52 30min 3 
9.
9 839 N DN SHT/DM C 7.9 3.3 
26.
07 
7.5
2 4.3 F N 
Mr. 
Chelladurai 
O10048
703 0.9 
1.0
7 
1
5 
1
3 
1
5 
1
4 57 52 M 7 M N 
3600
0 19 
1hr15
min 2 
8.
2 235 N 
not 
kno
wn SHT C 6.5 6.7 
43.
55 
8.4
2 4.3 F N 
Mr. 
Sathishkumar 
O11029
550 1.2 
1.6
5 
1
1 
1
3 
1
5 
1
2 51 30 M 10 M E 
2400
00 7 1hr 3 
7.
5 73 N 
not 
kno
wn SHT C 9.2 6.4 
58.
88 
8.4
5 4.4 F 
8000
U 
Mr. 
Gunasekaran 
O02041
619 1.1 
2.5
6 
1
4 
1
3 8 
1
3 48 34 M 10 M E 
1000
00 91 
1hr30
min 3 
1
0 ## N 
not 
kno
wn SHT C 10 6.6 
66.
66 11 4.5 F N 
Mrs. 
Angammal 
O06033
021 1.6 
1.4
3 
1
2 
1
3 
1
3 
1
3 51 60 F 10 M N 
3600
00 66 1hr 3 
9.
6 778 N 
not 
kno
wn SHT C 10 3.3 
34.
32 
8.1
7 3.7 F 
8000
U 
Mr.Dharmaraj 
O10029
853 1.7 
0.9
4 
1
0 9 
1
2 9 40 24 M B.COM N E 
8400
0 15 30min 2 
5.
6 33 N DN SHT/DM C 7.7 4.5 
34.
65 
4.9
6 2.5 C 
8000
U 
Mr.Thangaras
u 
O09004
459 1.3 
0.9
4 
1
1 9 7 
1
2 39 52 M 10 M N 
1000
00 15 3hrs 2 8 291 N 
not 
kno
wn SHT C 7.5 6.2 
46.
5 
13.
2 3.9 F 
4000
U 
Mr.Venugopal 
O10023
713 0.9 
1.6
4 
1
2 
1
1 
1
5 
1
3 51 64 M 0 M N 
1200
00 22 1hr 3 
1
1 520 N DN SHT/DM C 9 6.3 
56.
7 
10.
7 4.2 F N 
Mr.Kirubanand
ham 
O05041
570 1 
1.2
1 
1
4 
1
2 9 
1
4 49 35 M ITI M E 
5000
0 44 1hr 3 
6.
4 125 N 
not 
kno
wn SHT C 6.4 4.1 
26.
24 
10.
5 4 F N 
Mr.Gopal 
O01045
815 1.2 1.2 
1
3 
1
0 
1
2 
1
5 50 61 M 9 M N 
1300
00 36 
1hr30
min 3 
1
0 109 N DN SHT/DM C 8.8 6.1 
53.
68 
7.7
1 3.7 F 
8000
U 
Mr.Gopal raj 
O10054
725 1.2 
1.6
9 9 9 
1
1 
1
0 39 60 M 10 M N 
6000
0 6 45min 3 
1
0 302 N DN SHT/DM C 9.2 3.4 
31.
28 
6.4
8 3.9 F 
8000
U 
Mrs.Kaliammal 
O06040
243 1.1 
2.2
9 
1
1 
1
1 9 
1
4 45 67 F 10 M N 
1000
00 71 45min 3 
9.
6 178 N DN SHT/DM C 8.6 3.8 
32.
68 
5.0
9 3.4 F N 
Mr.Yuvaraj 
O10081
693 1.3 
1.0
1 
1
2 
1
1 9 9 41 47 M 5 M N 
6000
0 20 45min 2 
6.
9   N 
not 
kno
wn SHT C 8.9 7.2 
64.
08 
4.4
5 4.2 F N 
Mr. 
Chinnasamy 
O07060
273 2 
1.1
5 
1
2 
1
3 
1
2 
1
4 51 61 M 5 M E 
1000
0 52 30min 3 
9.
9 839 N DN SHT/DM C 7.9 3.3 
26.
07 
7.5
2 4.3 F N 
Mr.Sharif 
O09077
352 1.4 
1.5
3 
1
5 
1
3 
1
5 
1
5 58 37 M 10 M N 
2500
00 28 2hrs 2 
7.
6 461 N 
not 
kno
wn SHT C 9.8 6.5 
63.
7 
11.
9 4.6 F 
8000
U 
 

 
